| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AIMD Stock Overview
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.
Ainos Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$1.20 |
| 52 Week Low | US$0.083 |
| Beta | 1.08 |
| 1 Month Change | 75.00% |
| 3 Month Change | 42.86% |
| 1 Year Change | -26.32% |
| 3 Year Change | 57.23% |
| 5 Year Change | 150.00% |
| Change since IPO | -99.26% |
Recent News & Updates
Shareholder Returns
| AIMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.5% | 5.7% | 1.0% |
| 1Y | -26.3% | -24.5% | -12.9% |
Return vs Industry: AIMD underperformed the US Biotechs industry which returned -24.5% over the past year.
Return vs Market: AIMD underperformed the US Market which returned -12.9% over the past year.
Price Volatility
| AIMD volatility | |
|---|---|
| AIMD Average Weekly Movement | 103.3% |
| Biotechs Industry Average Movement | 12.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AIMD is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 46% a day.
Volatility Over Time: AIMD's weekly volatility has increased from 68% to 103% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 35 | Chun-Hsien Tsai | https://ainos.com |
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.
Ainos Fundamentals Summary
| AIMD fundamental statistics | |
|---|---|
| Market Cap | US$101.07m |
| Earnings (TTM) | -US$5.45m |
| Revenue (TTM) | US$679.64k |
148.9x
P/S Ratio-18.5x
P/E RatioIs AIMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIMD income statement (TTM) | |
|---|---|
| Revenue | US$679.64k |
| Cost of Revenue | US$224.01k |
| Gross Profit | US$455.63k |
| Other Expenses | US$5.91m |
| Earnings | -US$5.45m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 67.04% |
| Net Profit Margin | -802.56% |
| Debt/Equity Ratio | 387.1% |
How did AIMD perform over the long term?
See historical performance and comparisonValuation
Is AIMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AIMD?
Other financial metrics that can be useful for relative valuation.
| What is AIMD's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$101.07m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 192x |
| Enterprise Value/EBITDA | -58.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does AIMD's PB Ratio compare to its peers?
| AIMD PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
OCX OncoCyte | 2.1x | 10.0% | US$121.2m |
SLDB Solid Biosciences | 0.5x | -9.8% | US$85.6m |
ATNM Actinium Pharmaceuticals | 2x | 79.5% | US$136.3m |
MBIO Mustang Bio | 0.8x | 14.8% | US$78.3m |
AIMD Ainos | 12.5x | n/a | US$101.1m |
Price-To-Book vs Peers: AIMD is expensive based on its Price-To-Book Ratio (12.5x) compared to the peer average (1.3x).
Price to Earnings Ratio vs Industry
How does AIMD's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: AIMD is expensive based on its Price-To-Book Ratio (12.5x) compared to the US Biotechs industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is AIMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 12.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate AIMD's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AIMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AIMD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AIMD's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Ainos forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
11.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ainos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of AIMD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Ainos's filings and announcements here.
Past Performance
How has Ainos performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-36.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AIMD is currently unprofitable.
Growing Profit Margin: AIMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AIMD is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year.
Accelerating Growth: Unable to compare AIMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AIMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).
Return on Equity
High ROE: AIMD has a negative Return on Equity (-67.49%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Ainos's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AIMD's short term assets ($3.0M) do not cover its short term liabilities ($5.7M).
Long Term Liabilities: AIMD's short term assets ($3.0M) do not cover its long term liabilities ($26.9M).
Debt to Equity History and Analysis
Debt Level: AIMD's net debt to equity ratio (364%) is considered high.
Reducing Debt: AIMD had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AIMD has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AIMD is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Dividend
What is Ainos's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AIMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AIMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AIMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AIMD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AIMD has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average management tenure
CEO
Chun-Hsien Tsai (52 yo)
1.33yrs
Tenure
US$81,616
Compensation
Mr. Chun-Hsien Tsai has been Chairman of Board, President and Chief Executive Officer at Ainos, Inc. since April 15, 2021 and served as its Chief Financial Officer since April 15, 2021 until August 11, 202...
CEO Compensation Analysis
Compensation vs Market: Chun-Hsien's total compensation ($USD81.62K) is below average for companies of similar size in the US market ($USD767.73K).
Compensation vs Earnings: Insufficient data to compare Chun-Hsien's compensation with company performance.
Leadership Team
Experienced Management: AIMD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
Experienced Board: AIMD's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Ainos, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Ainos, Inc.
- Ticker: AIMD
- Exchange: OTCPK
- Founded: 1984
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$101.066m
- Shares outstanding: 144.38m
- Website: https://ainos.com
Number of Employees
Location
- Ainos, Inc.
- 8880 Rio San Diego Drive
- Suite 800
- San Diego
- California
- 92108
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/07 00:00 |
| End of Day Share Price | 2022/08/05 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.